Abstract
These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this biological information rich and functional knowledge poor scenario, the challenges are indeed grand, no less than the assembly of the genome of the whole organism. These include functional annotation of genes, identification of druggable targets, prediction of three-dimensional structures of protein targets from their amino acid sequences, arriving at lead compounds for these targets followed by a transition from bench to bedside. We propose here a “Genome to Hits In Silico” strategy (called Dhanvantari) and illustrate it on Chikungunya virus (CHIKV). “Genome to hits” is a novel pathway incorporating a series of steps such as gene prediction, protein tertiary structure determination, active site identification, hit molecule generation, docking and scoring of hits to arrive at lead compounds. The current state of the art for each of the steps in the pathway is high-lighted and the feasibility of creating an automated genome to hits assembly line is discussed.
Keywords: Genome annotation, protein folding, docking and scoring, lead molecule, CHIKV.
Current Pharmaceutical Design
Title:Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya
Volume: 19 Issue: 26
Author(s): Anjali Soni, Khushhali M. Pandey, Pratima Ray and B. Jayaram
Affiliation:
Keywords: Genome annotation, protein folding, docking and scoring, lead molecule, CHIKV.
Abstract: These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this biological information rich and functional knowledge poor scenario, the challenges are indeed grand, no less than the assembly of the genome of the whole organism. These include functional annotation of genes, identification of druggable targets, prediction of three-dimensional structures of protein targets from their amino acid sequences, arriving at lead compounds for these targets followed by a transition from bench to bedside. We propose here a “Genome to Hits In Silico” strategy (called Dhanvantari) and illustrate it on Chikungunya virus (CHIKV). “Genome to hits” is a novel pathway incorporating a series of steps such as gene prediction, protein tertiary structure determination, active site identification, hit molecule generation, docking and scoring of hits to arrive at lead compounds. The current state of the art for each of the steps in the pathway is high-lighted and the feasibility of creating an automated genome to hits assembly line is discussed.
Export Options
About this article
Cite this article as:
Soni Anjali, Pandey M. Khushhali, Ray Pratima and Jayaram B., Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya, Current Pharmaceutical Design 2013; 19 (26) . https://dx.doi.org/10.2174/13816128113199990379
DOI https://dx.doi.org/10.2174/13816128113199990379 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Strategies in Pulmonary Hypertension of the Newborn: Where Are We Now?
Current Medicinal Chemistry mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways
Current Neurovascular Research Editorial (Hot Topic: Treatment of Atherosclerosis as an Inflammatory Disease)
Current Pharmaceutical Design Tetherin/BST-2: Restriction Factor or Immunomodulator?
Current HIV Research Evaluation of Oxidative Stress Biomarkers in Brain Metastatic and Non-Metastatic Lung Cancer Patients with Different Cell Types
Anti-Cancer Agents in Medicinal Chemistry Novel Prodrugs for the Treatment of Colonic Diseases Based on 5-Aminosalicylic Acid, 4'-eranyloxyferulic Acid, and Auraptene: Biological Activities and Analytical Assays
Current Drug Delivery Epithelial Cell-Derived Antibacterial Peptides Human β-Defensins and Cathelicidin: Multifunctional Activities on Mast Cells
Current Drug Targets - Inflammation & Allergy Neuroprotective Effects of an Erythropoietin-Derived Peptide in PC1 2 Cells under Oxidative Stress
CNS & Neurological Disorders - Drug Targets Effects of <i>CYP3A5</i> Genetic Polymorphisms on the Weight-adjusted through Concentration of Sirolimus in Renal Transplant Recipients: A Systematic Review and Meta-analysis
Current Pharmaceutical Design Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
CNS & Neurological Disorders - Drug Targets Role of Rifaximin in Inflammatory Bowel Disease Treatment
Mini-Reviews in Medicinal Chemistry Advances in Biologic Agents for the Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Computational Techniques for Diversity Analysis and Compound Classification
Mini-Reviews in Medicinal Chemistry Osteoblast Differentiation and Control by Vitamin D and Vitamin D Metabolites
Current Pharmaceutical Design The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
Current Cancer Drug Targets Innate Immune Receptors and IRF Family Transcription Factors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Potential Applications of <i>Sarcopoterium Spinosum</i> as Medicinal Plants: Overview and Future Trends
Current Traditional Medicine Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry